AntiCancer Announces New Fluorescence Technology Developed For Curative Pancreatic Cancer Surgery

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has announced the development of new technology of combining fluorescence-guided surgery (FGS) of pancreatic cancer with ultraviolet light radiation to eliminate any residual cancer cells remaining after the surgery in mouse models of human pancreatic cancer. AntiCancer is a world leader in both mouse models of human cancer that represent the patient and the development of technology to make tumors fluorescent, allowing the surgeon to visualize the cancer much better than previously possible. “This is a breakthrough in pancreatic cancer surgery that enables the surgeon to visualize the cancer by making it fluorescent, and thereby allows the cancer to better absorb and become sensitive to ultraviolet light, which eradicates any remaining cancer cells not removed by the surgeon in the area of the tumor. This new technology was developed in mouse models of human pancreatic cancer and its application in the clinic could take place in the near future and should improve patient outcome in this highly lethal disease,” said Charlene M. Cooper, spokesperson of AntiCancer Inc. This new technology is described in the new issue of PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0099977).

Help employers find you! Check out all the jobs and post your resume.